Extensive biliary intraepithelial neoplasia (BilIN) and multifocal early intrahepatic cholangiocarcinoma in non-biliary cirrhosis by Rougemont, Anne-Laure et al.
CASE REPORT
Extensive biliary intraepithelial neoplasia (BilIN)
and multifocal early intrahepatic cholangiocarcinoma
in non-biliary cirrhosis
Anne-Laure Rougemont & Muriel Genevay &
Thomas A. McKee & Magali Gremaud & Gilles Mentha &
Laura Rubbia-Brandt
Received: 23 September 2009 /Revised: 14 January 2010 /Accepted: 20 February 2010 /Published online: 29 April 2010
# Springer-Verlag 2010
Abstract Biliary intraepithelial neoplasia (BilIN), a preneo-
plastic condition that may precede invasive intrahepatic
cholangiocarcinoma (ICC), has been compared to pancreatic
intraepithelial neoplasia (PanIN), a precursor lesion of
pancreatic carcinoma. Biliary tract carcinoma development
and progression is associated with several gene alterations,
but BilIN lesions have yet to be studied in detail by molecular
techniques. We describe a case of extensive intrahepatic
biliary dysplasia, with lesions ranging from BilIN-1 to BilIN-
3 lesions, and multifocal microscopic ICC in hepatitis C virus
(HCV)- and alcohol-related cirrhosis. The small ICC foci had
remained undetected prior to transplantation. Fluorescence in
situ hybridization (FISH) analysis was performed on three
foci of BilIN-3 lesions and on three microinvasive ICC foci
with a combination of three FISH probes directed against
genes frequently altered in pancreatic and biliary tract
carcinomas. FISH analysis revealed a CDKNA2 heterozygous
deletion in one BilIN-3 focus, and in one non-contiguous
ICC focus, although the deletion was just above the chosen
threshold. No deletions were detected in the genomic regions
encoding TP53 and SMAD4. This report documents for the
first time the development of multifocal ICC in the setting of
extensive biliary dysplasia in a patient with three risk factors,
HCV infection, alcohol abuse, and cirrhosis, and suggests
heterogeneous carcinogenesis in ICC and possible involve-
ment of the CDKNA2 gene.
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Introduction
Intra- and extrahepatic cholangiocarcinoma can arise from
two main premalignant conditions, flat or low-papillary
biliary dysplasia (biliary intraepithelial neoplasia, BilIN)
and intraductal papillary neoplasm (IPN) [1, 2]. IPN, a
macroscopically visible papillary proliferation, is consid-
ered to be a counterpart of pancreatic intraductal papillary
mucinous neoplasm (IPMN) [2], while morphological and
immunophenotypic similarities suggest that BilIN could be
related to pancreatic intraepithelial neoplasia (PanIN) [3].
BilIN may further progress to cholangiocarcinoma with
features of tubular adenocarcinoma [3], mirroring the
multistep carcinogenesis progression of PanIN. The three-
tiered grading system (BilIN-1 to BilIN-3) depends mainly
on the degree of cytological atypia and corresponds
respectively to mild, moderate, and severe dysplasia [2,
4]. Invasive adenocarcinoma defines intrahepatic cholan-
giocarcinoma (ICC).
Risk factors for ICC include chronic biliary disease, such
as hepatolithiasis or primary sclerosing cholangitis (PSC),
liver fluke infestation, biliary cysts, and bile duct dilatation
(such as Caroli’s disease or choledochal cyst) or Thorotrast
deposition [5, 6]. A “hyperplasia–dysplasia–carcinoma”
sequence has been reported in such conditions [6]. BilIN
lesions have been initially described mainly in the setting of
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PSC [7–9], with biliary dysplasia representing a potential
marker for concomitant or later-occurring CC [10]. Several
arguments point to a major role for hepatitis C virus (HCV)
infection in ICC pathogenesis, including epidemiological
correlations [11]; the recent identification of biliary dyspla-
sia in HCV-related cirrhotic livers [12, 13]; the detection of
HCV RNA in ICC [14]; and the detection of HCV core
proteins by immunohistochemistry in ductular cells in
HCV-positive patients [15]. HCV-positive patients have a
2.55-fold increased risk of ICC development, while
hepatocellular carcinoma (HCC) risk is increased 15-fold
[16]. HCV-positive patients are also at risk for large B cell
lymphoma, albeit rarely [17]. ICC in the setting of viral
hepatitis or cirrhosis mostly originates from the periphery
of the liver [11, 18].
The high sensitivity of a combination of three fluores-
cence in situ hybridization (FISH) probes in the diagnosis
of pancreatic adenocarcinoma has been recently described
by our group [19]. The rationale for the choice of the three
FISH probes was the frequent occurrence of mutations in
the TP53 (encoding p53), CDKN2A (encoding p16(INK4a)
and p14(ARF)) and DPC4/SMAD4 (encoding Dpc4) tumor
suppressor genes in both pancreatic and biliary tract
malignancy [20–23]. It is noteworthy that these gene
alterations have also been described in PanIN lesions [24].
Analysis using these probes was intended to clarify the
relationship between BilIN with ICC, and PanIN with
pancreatic adenocarcinoma.
We describe here a case of mild to severe dysplasia
BilIN lesions (BilIN-1 to BilIN-3) with microinvasive ICC
foci, in the setting of HCV- and alcohol-related cirrhosis.
We report on the results of a FISH analysis of this dysplasia
to invasive neoplasia sequence using the TP53, CDK2NA,
and MALT1 (used as a surrogate for SMAD4) probes.
Clinical report
A 42-year-old man underwent liver transplantation for
Child C cirrhosis. HCV conversion followed a 5-year drug
abuse period, between ages 24 and 29. He had a past
history of alcohol abuse. Cirrhosis complications included
ascites, esophageal varices, and hepatic encephalopathy
while on the waiting list for liver transplantation. Imaging
was consistent with cirrhosis, but revealed no focal lesions.
Liver tests during pre-transplantation evaluation were
nearly within normal ranges (aspartate aminotransferase
97 U/L, alanine transaminase 57 U/L, alkaline phosphatase
85 U/L; γ-glutamyltransferase 20 U/L, total bilirubin
184 μmol/L, conjugated bilirubin 75 μmol/L). Evolution
was unfavorable, with hypovolemic shock and septicemia,
and the patient died 16 days after transplantation from
central pontine myelinolysis, despite normal liver function.
Materials and methods
Representative sections from the liver explant were rou-
tinely processed, fixed in 10% buffered formalin and
paraffin embedded. For routine histological examination,
3-μm-thick sections were stained with hematoxylin–eosin
(H&E), and with the following special stains: Masson
trichrome, reticulin stain, PAS with prior diastase digestion,
and a Pearl’s blue stain. H&E slides allowed selection of
three different BilIN-3 foci and of three different ICC foci.
One of each of these two lesions was selected on three
different representative slides. We chose to initially focus
this study on lesions with a higher degree of dysplasia, with
further analysis of BilIN-1 and BilIN-2 lesions as a second
step, should the initial FISH evaluation reveal major
alterations.
The FISH probes were ordered from Vysis, Inc®
(Downers Grove, IL). The protocol applied was the same
as provided in the study by Genevay et al. [19]. Four
micrometer thick tissue sections were placed on Super-
frost® Plus (Menzel Glasser®) coated slides, dewaxed,
rehydrated, and then immersed successively in two baths of
100% ethanol (5 min at room temperature). The slides were
then dried and incubated in Vysis “pre-treatment solution”
at 80°C for 15 min, washed in distilled water for 2 min, and
dried at 45°C. Tissue sections were then digested with
protease at 37°C 60 min for LSI-p16 (CDKN2A); 90 min
for LSI-MALT1 (18q21); and 105 min for LSI p53 (17p13)
and washed in distilled water for 2 min. Subsequently, they
were dehydrated by successive immersions in 70%, 80%,
and 100% ethanol (2 min each at room temperature). Probe
mixtures were then separately prepared by mixing 1-µl
probe with 7 µl hybridization buffer and 2 µl purified water.
The LSI p16/CEP9 Dual Color Probe is a mixture of the
LSI p16 probe labeled with SpectrumOrange and the CEP9
probe labeled with SpectrumGreen. The chromosome nine
centromeric region probe (CEP9) served as an internal
control. Accordingly, labeled probes specific to the
pericentromeric region of chromosomes 17 (CEP17) and
18 (CEP18) were used as internal controls for the
SpectrumOrange TP53 probe (CEP17) and for the Spec-
trumOrange MALT1 probe (CEP18), respectively. One
microliter of CEP17 was placed in 10 µl of LSI-p53 probe
mixture, and 1 µl of CEP18 was placed in LSI-MALT1
probe mixture. The MALT1 gene, located at 18q21, is
separated from the SMAD4 gene by 10 Mb. The use of the
commercially available MALT probe seemed reasonable,
given this relatively small separation between the two
genes, and since a loss of heterozygosity at 18q is
described in PanIN lesions [24]. Seven microliters of
probe mixture was placed onto the denatured slides and
covered with glass coverslips. Hybridization was carried
out in a humidified chamber at 72°C for 15 min. The
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slides were then washed in post-hybridization wash buffer
and incubated in wash buffer for 3 min at 75°C, then
washed in distilled water. Subsequently, 7 µl of DAPI
counterstain was placed on the slides, which were then
mounted with glass coverslips. After hybridization, all
slides were stored in the dark at −20°C. As final
procedure, the slides were counterstained with DAPI.
Analysis was performed with a Zeiss® Axioplan two
fluorescence microscope equipped with 10×, 20×, 60×, and
100× objectives and specific filters (Yellow simple band,
Aqua simple band, DAPI simple band, and green/red
double band). Image capture was provided by the IP Lab
for Macintosch software (Scanalytics® Inc; Rockville,
MD). FISH signal counts were repeated on three different
BilIN-3 foci, and on three different ICC foci, one of each
from three different representative slides. The different foci
were located with the DAPI counterstaining and compari-
son to the original H&E slides. Hybridization signals were
counted in at least 200 BilIN-3 dysplastic cell nuclei and
200 adenocarcinoma cells per focus. Genes were consid-
ered deleted or amplified when ≤1 or ≥3 nuclear signals
were detected, respectively. The cutoff values defined by
our group with a receiver operating characteristic (ROC)
curves analysis (AUC), and providing a specificity >90%
for all three probes, were applied [19]. In this previous
study, the ROC curves were calculated using Medcalc®
v9.6.4.0. The value for the area under the curve (AUC) had
to be at least 0.5 for the test to be considered as efficient.
The cutoff value (the minimum percentage of cells
exhibiting deletions or amplifications required to consider
the test result as positive) was chosen to maximize the test
specificity (at least 90%).
Accordingly, from the results of this previous study, the
following thresholds were chosen: 7% for the LSI-MALT1
and LSI-p16 probes and 17% for the LSI-p53 probe. With
these criteria, a FISH sensitivity of 82% and specificity of
100% had been obtained in the diagnosis of pancreatic
adenocarcinoma when ≥2 genetic modifications were
observed [19]. Although no FISH data exists to date in
PanIN lesions, alterations have been shown in the three
selected regions in PanIN lesions [23, 25–27].
Results
Upon gross examination, the liver weighed 1,053 g and
showed a micronodular cirrhosis, with no overtly malignant
macronodules on cut section. Multiple white nodules
measuring up to 0.5 cm in greatest diameter were observed
in both lobes, mostly in peripheral locations (Fig. 1). No
papillary proliferation was grossly visible in bile ducts.
Upon histological evaluation, the cirrhosis was confirmed
using Masson trichrome and reticulin stains, and a mainly
lymphocytic portal tract infiltrate with no hepatitis activity
was observed (METAVIR score A0-F4) [28] with H&E.
There was mild iron deposition in hepatocytes, owing to
cirrhosis, and no hyaline globules. A strikingly diffuse flat
or pseudo-papillary proliferation of the biliary epithelium
with mucosecretion in a minority of cells involved larger
intrahepatic biliary tracts and extended to the interlobular
ducts (Fig. 2a). These features were observed both in
peripheral and central locations, with sparing of the large
perihilar bile ducts. Cytological changes ranged from mild,
with basally located slightly elongated nuclei (BilIN-1), to
severe, with hyperchromatic and large nuclei and loss of
cell polarity (BilIN-3) (Fig. 2b–c). Additional small foci
consisted of a proliferation of angular and irregular glands,
surrounded by a stromal reaction consistent with stromal
invasion (Fig. 2d). These ICC foci were distinguished from
ductular reaction by: 1) the presence of irregular and
angulated glands, with an open lumen; 2) a higher degree
of cytonuclear atypia; and 3) the identification of a
desmoplastic reaction. Fibrosis in such areas was promi-
nent, and correlated with microscopic zones in some of the
grossly identified fibrotic white nodules. There was no
evidence of alcohol-related lesions.
FISH analysis in the 200 or more cell nuclei showed
CDKN2A heterozygous deletion above the 7% threshold in
one of the three chosen BilIN-3 foci (10% of cell nuclei)
and in one of the three ICC foci (8.5% of cells) (Fig. 3).
Loss of one TP53 signal was observed in 13.8 and 15% of
the nuclei analyzed in 2 ICC foci, and in 15.9% of one
BilIN-3 focus, but failed to attain the previously defined
cutoff value of 17%. MALT1 showed a normal FISH signal
in all the BilIN-3 and ICC foci. In view of these results,
shown in Table 1, no further analysis of BilIN-1 and BilIN-
2 lesions was performed.
Fig. 1 Gross findings of liver cirrhosis and multiple white nodules,
measuring up to 0.5 cm in greatest diameter and mostly located at the
periphery (black arrows)
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Discussion
We report here the first case of extensive BilIN lesions with
multiple microscopic ICC foci, in the setting of HCV- and
alcohol-related cirrhosis. BilIN lesions extended from
septal-sized to interlobular bile ducts. Multiple ICC foci
were located in the two lobes. A CDKN2A heterozygous
deletion was observed in one BilIN-3 focus and in one non-
contiguous ICC focus. No TP53 or MALT1 deletion was
observed.
BilIN is a rare finding in cirrhotic livers. In a large
retrospective study of 1,058 liver explants by Torbenson et
al., dysplasia was observed in 1.8% of cases, and only in
cirrhotic livers [12]. Addition of alcohol consumption to
HCV infection increased the incidence of bile duct
dysplasia from 2% (HCV infection alone) to 5% (HCV
and alcohol) [12]. Multifocal dysplastic changes involved
only septal-sized bile ducts [12]. In a series of 468 cases of
liver cirrhosis, in patients lacking a history of cholangitis or
hepatolithiasis, Aishima et al. identified two cases of high-
grade biliary dysplasia with a micropapillary growth pattern
and extensive spread [13]. The lesions involved the intra-
hepatic septal ducts, the interlobular ducts, and the ductules
of the ductular reaction, and had developed in one case in a
HCV-related cirrhotic liver, with two HCC, and in the
second case, in a liver with alcohol-related cirrhosis [13].
No ICC foci were described. The case presented here thus
represents the third description of multifocal BilIN lesion in
non-biliary cirrhotic liver, involving not only septal-sized
bile ducts, but also interlobular bile ducts, and the first with
co-existent ICC foci.
ICC microinvasive foci are difficult to diagnose on
morphological aspects solely, and we wished to determine
whether FISH techniques might be of diagnostic value. The
Fig. 2 Histological progression from BilIN lesions to ICC, according
to the criteria by Zen et al. [2] hematoxylin & eosin (H&E). a
Multifocal flat or pseudo-papillary proliferation of the biliary
epithelium, extending from the segmental bile ducts to the interlobular
ducts (original magnification 100×). b BilIN-2 (400×). c BilIN-3
(200×). d Microinvasive ICC focus, identified at low power (100×)
and confirmed at higher power (inset—400×). Inset illustrates the
distorted, angulated and branching glands, with an open lumen, and
the stromal invasion
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proposed relationship between these lesions and PanIN/
pancreatic carcinoma justified the use of probes directed
against genes involved both in pancreatic and biliary tract
oncogenetic pathways [20–23]. Several studies have con-
firmed the importance of allelic losses at 9p21 (CDKN2A),
17p13 (TP53), and 18q21 (SMAD4) in pancreatic carcino-
ma, with loss of one or more of these loci in a vast majority
of cases [29–33]. Early loss of CDKN2A has been shown in
the PanIN to pancreatic adenocarcinoma sequence, with
TP53 and SMAD4 being deleted later [23–27]. In invasive
biliary tract tumors, or in their metastases, losses of regions
harboring each of the three genes studied have been
demonstrated in 64% (9p), 45% (17p), and 55% (18q) of
cases [22]. This, along with the absence of deletions in the
majority of lesions studied in this case, suggests molecular
differences in pancreatic and biliary tract oncogenesis with
chromosomal deletion, possibly occurring later in the
pathway.
CDKN2A gene alterations are described in many cancer
types [34]. Homozygous 9p21 deletion, encompassing the
CDKN2A gene, was observed in 11 of 22 ICC by FISH
analysis, of which 16 were sporadic and the remaining six
were PSC related [35]. Homozygous 9p21 deletion has also
been described in three of five PSC-related biliary dysplasia
specimens [35]. We observed a CDKN2A heterozygous
deletion in a subset of the BilIN-3 and ICC foci. These
findings evoke the possibility of involvement of different
molecular pathways from one ICC focus to another, as has
been described in cases of synchronous multicentric HCC
[36].
A progressive decrease in immunohistochemical reactiv-
ity of Dpc4 expression, the SMAD4 gene protein product,
has been observed from non-neoplastic biliary epithelium to
invasive CC [37]. Despite this previous description, we
observed no alteration in the MALT1 gene, used as a
surrogate for SMAD4, suggesting that at least part of the
reduction of protein expression might result from point
mutations or epigenetic inactivation.
Inactivating TP53 mutations represent the most frequent
gene alteration in human cancers [38]. TP53 mutations
have been detected particularly in the mass-forming ICC
type in the setting of viral hepatitis, suggesting a relation-
ship to ICC arising from small peripheral bile ducts [5, 39].
However, the alterations observed were missense or, rarely,
nonsense mutations [39]. We observed no TP53 alteration
in the case reported here.
We described here a third case of extensive BilIN lesions
in the setting of HCV- and alcohol-related cirrhosis.
Multiple microscopic ICC foci were too small to allow
radiological detection. BilIN has recently been described in
non-biliary liver cirrhosis, and as described in PSC patients,
dysplasia in liver biopsy specimens might be a marker of
synchronous or metachronous ICC. However, BilIN may
affect only the rarely biopsied segmental bile ducts. FISH
techniques revealed a CDKN2A heterozygous deletion in
Fig. 3 FISH results, with the LSI p16 (CDKN2A) probe showing
heterozygous deletion in a subset of the ICC cells in a BilIN-3 focus,
with loss of one of the SpectrumOrange signals in a nucleus and
preservation of the 2 centromeric SpectrumGreen signals (white arrow)
Significance threshold LSI-p16 (CDKN2A) LSI-MALT1 (SMAD4 surrogate) LSI-p53
7% 7% 17%
BilIN-3 Focus 1 21/201 10% 0/202 16/155 10%
Focus 2 3/272 1.1% 4/201 1.9% 42/264 15.9%
Focus 3 2/213 0.9% 0/240 9/212 4%
ICC Focus 1 8/227 3.5% 0/300 26/188 13.8%
Focus 2 12/266 4.5% 2/201 0.9% 6/111 5.4%
Focus 3 13/152 8.5% 0/200 38/252 15%
Table 1 FISH analysis results,
in the cell nuclei of three
BilIN-3 and three ICC foci,
from three representative slides
(foci one to three)
Virchows Arch (2010) 456:711–717 715
one BilIN-3 and in one ICC focus. We hypothesize that
these CDKN2A alterations could represent a late event and
would have been more pronounced had the lesions
progressed to a more overt mass-forming ICC, in contrast
to observations in PanIN, where CDKN2A alterations
appear to be an early event. Heterogeneous findings were
observed in the different BilIN-3 and ICC foci studied,
evoking the possibility of involvement of different molec-
ular pathways from one ICC focus to another, as has been
described in cases of synchronous multicentric HCC. BilIN
and PanIN share close phenotypic and immunohistochem-
ical aspects, and seem to share some oncogenic mecha-
nisms. However, the observation of heterogeneous
CDKN2A alterations and the absence of TP53 and MALT1
(surrogate for SMAD4) deletions in the case presented here
point towards different oncogenetic pathways. The study of
large numbers of lesions is warranted.
Conflict of interest statement We declare that we have no conflict
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